Trial Profile

A Randomized, Double-Masked, Multicenter, Two-Arm Study Comparing the Efficacy and Safety of RC28-E 2mg Versus Aflibercept in Subjects With Wet Age-Related Macular Degeneration

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 24 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 Aug 2026 Status changed to completed
06 Aug 2026 According to a Santen Pharmaceutical media release, STN1014301 (RC28-E; eflimrufusp alfa) is being developed for the treatment of wet age-related macular degeneration. RemeGen Co Ltd (China), the licensor, completed a phase 3 clinical trial in China in April 2026, with the study meeting its primary endpoint.
06 Aug 2026 Primary endpoint has been met (Mean change from baseline in BCVA at week 48) , according to a Santen Pharmaceuticals media release

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com